- CONTACT US
- AFS
- Business
- Bussiness
- Car
- Career
- Celebrity
- Digital Products
- Education
- Entertainment
- Fashion
- Film
- Food
- Fun
- Games
- General Health
- Health
- Health Awareness
- Healthy
- Healthy Lifestyle
- History Facts
- Household Appliances
- Internet
- Investment
- Law
- Lifestyle
- Loans&Mortgages
- Luxury Life Style
- movie
- Music
- Nature
- News
- Opinion
- Pet
- Plant
- Politics
- Recommends
- Science
- Self-care
- services
- Smart Phone
- Sports
- Style
- Technology
- tire
- Travel
- US
- World

Dec 9 (Reuters) - CVS Health (CVS) on Tuesday forecast 2026 profit above Wall Street estimates and this year's projected earnings, signalling steady progress in the health conglomerate's turnaround plan.
CVS stock rose 5% in early trading on Tuesday.
The company in October projected double-digit earnings growth for 2026 after raising its 2025 profit forecast for the third time.
"We are closing out 2025 with meaningful momentum across our businesses and we expect another year of strong earnings growth in 2026," said Chief Financial Officer Brian Newman on Tuesday.
The company forecast 2026 adjusted profit to be in the range of $7.00 to $7.20 per share, compared with analysts' average estimate of $7.16, according to data compiled by LSEG.
It, however, expects total revenue of at least $400 billion next year, below analysts' average estimate of $419.26 billion.
CVS also raised its 2025 adjusted profit forecast to $6.60 to $6.70 per share from $6.55 to $6.65 previously.
(Reporting by Sneha S K in Bengaluru; Editing by Shinjini Ganguli)
LATEST POSTS
- 1
Let them eat (Taylor Swift) cake: The baker turning A-listers into life-size desserts - 2
King Charles shares cancer treatment update, says it's a 'personal blessing' - 3
Early diagnosis leads King Charles to scale back cancer treatment in the new year - 4
Mont Blanc road tunnel reopens to traffic after 15 weeks of repairs - 5
Bavarian leader questions Germany's Eurovision participation
Europe's powerful Ariane 6 rocket launches Sentinel-1D Earth-observation satellite to orbit (video)
Shah Capital pushes for Novavax sale, warns of proxy fight
Cyber Monday 2025: Save over 70% on HBO Max with this Prime Video streaming deal
Seven deaths possibly linked to malfunctioning glucose monitors
AstraZeneca to invest $2 billion as part of US manufacturing push
Analysis-From 'Icarus bug' to flawed panels: Airbus counts cost of relying on single model
FDA adds strongest warning to Sarepta gene therapy linked to 2 patient deaths
Emergent Cold LatAm opens state-of-the-art cold storage hub in Guadalajara
US FDA panel to weigh bid to market nicotine pouches as lower-risk than cigarettes













